University of Miami Miller School of Medicine, United States; Research Service, Bruce W. Carter VA Medical Center, Miami, FL, United States.
University of Miami Miller School of Medicine, United States.
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Oct 3;70:111-6. doi: 10.1016/j.pnpbp.2016.02.008. Epub 2016 Feb 27.
Approximately 30% of people with schizophrenia manifest a minimal response to conventional and atypical antipsychotic medications and manifest continuous symptoms of psychosis, with this condition referred to as "treatment resistant schizophrenia (TRS)". There are several neurobiological consequences of continuous psychosis, including regional cortical atrophy and ventricular enlargement. Pharmacological treatments are available for TRS, with at least 1/3 of patients responding to treatment with clozapine. In this paper we review the evidence regarding the course of treatment resistant schizophrenia, as well as changes in brain structure and function in psychosis and on the possible role of clozapine treatment in altering cortical deterioration in patients with TRS.
约 30%的精神分裂症患者对传统和非典型抗精神病药物表现出微小反应,并表现出持续的精神病症状,这种情况被称为“治疗抵抗性精神分裂症(TRS)”。持续的精神病有几个神经生物学后果,包括区域性皮质萎缩和脑室扩大。TRS 有多种药物治疗方法,至少有 1/3 的患者对氯氮平治疗有反应。本文综述了治疗抵抗性精神分裂症的病程以及精神病患者大脑结构和功能变化的证据,以及氯氮平治疗在改变 TRS 患者皮质恶化中的可能作用。